You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePirfenidone
Accession NumberDB04951
TypeSmall Molecule
GroupsInvestigational
DescriptionPirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Esbrietcapsule267 mg/1oralGenentech, Inc.2014-10-16Not applicableUs
EsbrietCapsule, hard267 mgOral useRoche Registration Limited2011-02-28Not applicableEu
Esbrietcapsule267 mg/1oralInter Mune, Inc.2014-10-16Not applicableUs
EsbrietCapsule, hard267 mgOral useRoche Registration Limited2011-02-28Not applicableEu
Esbrietcapsule267 mgoralHoffmann La Roche Limited2013-01-08Not applicableCanada
EsbrietCapsule, hard267 mgOral useRoche Registration Limited2011-02-28Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIID7NLD2JX7U
CAS number53179-13-8
WeightAverage: 185.2218
Monoisotopic: 185.084063979
Chemical FormulaC12H11NO
InChI KeyInChIKey=ISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
IUPAC Name
5-methyl-1-phenyl-1,2-dihydropyridin-2-one
SMILES
CC1=CN(C(=O)C=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinones. These are compounds containing a pyridine ring, which bears a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentPyridinones
Alternative Parents
Substituents
  • Methylpyridine
  • Pyridinone
  • Dihydropyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of idiopathic pulmonary fibrosis (IPF).
PharmacodynamicsPirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).
Mechanism of actionPirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin. In addition, pirfenidone reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life2-2.5 hours
ClearanceNot Available
ToxicityGenerally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9932
Blood Brain Barrier+0.996
Caco-2 permeable+0.8614
P-glycoprotein substrateNon-substrate0.8193
P-glycoprotein inhibitor INon-inhibitor0.755
P-glycoprotein inhibitor IINon-inhibitor0.9177
Renal organic cation transporterNon-inhibitor0.8157
CYP450 2C9 substrateNon-substrate0.6638
CYP450 2D6 substrateNon-substrate0.8248
CYP450 3A4 substrateSubstrate0.6111
CYP450 1A2 substrateInhibitor0.9108
CYP450 2C9 inhibitorNon-inhibitor0.5982
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7166
CYP450 3A4 inhibitorNon-inhibitor0.775
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7633
Ames testNon AMES toxic0.7652
CarcinogenicityNon-carcinogens0.8992
BiodegradationNot ready biodegradable0.9112
Rat acute toxicity2.1330 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9784
hERG inhibition (predictor II)Non-inhibitor0.6301
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral267 mg/1
Capsuleoral267 mg
Capsule, hardOral use267 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7566729 No2009-04-222029-04-22Us
US7635707 No2009-04-222029-04-22Us
US7696236 No2007-12-182027-12-18Us
US7767225 No2006-09-222026-09-22Us
US7767700 No2007-12-182027-12-18Us
US7816383 No2010-01-082030-01-08Us
US7910610 No2010-01-082030-01-08Us
US7988994 No2006-09-222026-09-22Us
US8013002 No2010-01-082030-01-08Us
US8084475 No2010-01-082030-01-08Us
US8318780 No2010-01-082030-01-08Us
US8383150 No2006-09-222026-09-22Us
US8420674 No2007-12-182027-12-18Us
US8592462 No2009-04-222029-04-22Us
US8609701 No2009-04-222029-04-22Us
US8648098 No2010-01-082030-01-08Us
US8753679 No2006-09-222026-09-22Us
US8754109 No2010-01-082030-01-08Us
US8778947 No2013-08-302033-08-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.89 mg/mLALOGPS
logP2ALOGPS
logP2.14ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)-1.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity57 m3·mol-1ChemAxon
Polarizability20.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Hale ML, Margolin SB, Krakauer T, Roy CJ, Stiles BG: Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun. 2002 Jun;70(6):2989-94. [PubMed:12010989 ]
  2. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F: Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268-76. [PubMed:17906160 ]
External Links
ATC CodesL04AX05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbataceptThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Abatacept.
AbciximabPirfenidone may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Pirfenidone can be increased when it is combined with Abiraterone.
AcebutololPirfenidone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Aceclofenac.
AcenocoumarolPirfenidone may increase the anticoagulant activities of Acenocoumarol.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirfenidone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Pirfenidone.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pirfenidone.
Alendronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Alendronic acid.
AliskirenPirfenidone may decrease the antihypertensive activities of Aliskiren.
AlprenololPirfenidone may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Pirfenidone.
AmikacinPirfenidone may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmiloridePirfenidone may decrease the antihypertensive activities of Amiloride.
AnakinraThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.
AncrodPirfenidone may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pirfenidone.
Antithrombin III humanPirfenidone may increase the anticoagulant activities of Antithrombin III human.
ApixabanPirfenidone may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Apremilast.
ArdeparinPirfenidone may increase the anticoagulant activities of Ardeparin.
ArgatrobanPirfenidone may increase the anticoagulant activities of Argatroban.
ArotinololPirfenidone may decrease the antihypertensive activities of Arotinolol.
AtenololPirfenidone may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Pirfenidone.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pirfenidone.
AzithromycinThe serum concentration of Pirfenidone can be increased when it is combined with Azithromycin.
BalsalazidePirfenidone may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pirfenidone.
BecaplerminPirfenidone may increase the anticoagulant activities of Becaplermin.
BefunololPirfenidone may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirfenidone.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Pirfenidone.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pirfenidone.
BetaxololPirfenidone may decrease the antihypertensive activities of Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirfenidone.
BevantololPirfenidone may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Pirfenidone.
BisoprololPirfenidone may decrease the antihypertensive activities of Bisoprolol.
BivalirudinPirfenidone may increase the anticoagulant activities of Bivalirudin.
BopindololPirfenidone may decrease the antihypertensive activities of Bopindolol.
BortezomibThe serum concentration of Pirfenidone can be increased when it is combined with Bortezomib.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pirfenidone.
BufuralolPirfenidone may decrease the antihypertensive activities of Bufuralol.
BumetanidePirfenidone may decrease the diuretic activities of Bumetanide.
BupranololPirfenidone may decrease the antihypertensive activities of Bupranolol.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.
CaffeineThe serum concentration of Pirfenidone can be increased when it is combined with Caffeine.
CanakinumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Canakinumab.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Pirfenidone.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Pirfenidone.
CarbamazepineThe serum concentration of Pirfenidone can be decreased when it is combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Pirfenidone.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pirfenidone.
CarteololPirfenidone may decrease the antihypertensive activities of Carteolol.
CarvedilolPirfenidone may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pirfenidone.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pirfenidone.
CeliprololPirfenidone may decrease the antihypertensive activities of Celiprolol.
Certolizumab pegolPirfenidone may increase the immunosuppressive activities of Certolizumab pegol.
CertoparinPirfenidone may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pirfenidone.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Pirfenidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.
CiprofloxacinThe serum concentration of Pirfenidone can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.
Citric AcidPirfenidone may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Pirfenidone.
ClotrimazoleThe serum concentration of Pirfenidone can be increased when it is combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Pirfenidone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirfenidone.
CyclosporinePirfenidone may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with D-Limonene.
Dabigatran etexilatePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinPirfenidone may increase the anticoagulant activities of Dalteparin.
DanaparoidPirfenidone may increase the anticoagulant activities of Danaparoid.
DaunorubicinPirfenidone may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deferasirox.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pirfenidone.
DesirudinPirfenidone may increase the anticoagulant activities of Desirudin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirfenidone.
DesmopressinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Pirfenidone.
DextranPirfenidone may increase the anticoagulant activities of Dextran.
Dextran 40Pirfenidone may increase the anticoagulant activities of Dextran 40.
Dextran 70Pirfenidone may increase the anticoagulant activities of Dextran 70.
Dextran 75Pirfenidone may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pirfenidone.
DicoumarolPirfenidone may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirfenidone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Pirfenidone.
DigoxinDigoxin may decrease the cardiotoxic activities of Pirfenidone.
DihydrostreptomycinPirfenidone may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Pirfenidone.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.
DoxorubicinPirfenidone may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenonePirfenidone may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Droxicam.
Edetic AcidPirfenidone may increase the anticoagulant activities of Edetic Acid.
EdoxabanPirfenidone may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirfenidone.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pirfenidone.
EnoxaparinPirfenidone may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Epirizole.
EpirubicinPirfenidone may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenonePirfenidone may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Pirfenidone.
EsmololPirfenidone may decrease the antihypertensive activities of Esmolol.
Etacrynic acidPirfenidone may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.
Ethyl biscoumacetatePirfenidone may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pirfenidone.
EtofenamateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pirfenidone.
Evening primrose oilThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Pirfenidone is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pirfenidone.
FingolimodPirfenidone may increase the immunosuppressive activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pirfenidone.
FlunixinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pirfenidone.
FluvoxamineThe serum concentration of Pirfenidone can be increased when it is combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Pirfenidone.
Fondaparinux sodiumPirfenidone may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Pirfenidone.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pirfenidone.
FramycetinPirfenidone may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemidePirfenidone may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Pirfenidone.
GentamicinPirfenidone may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.
HeparinPirfenidone may increase the anticoagulant activities of Heparin.
HirulogPirfenidone may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Pirfenidone is combined with HMPL-004.
HydralazinePirfenidone may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Pirfenidone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirfenidone.
Hygromycin BPirfenidone may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pirfenidone.
IbuproxamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Icatibant.
IdarubicinPirfenidone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Pirfenidone.
IndenololPirfenidone may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pirfenidone.
IndoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.
IsoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Isoxicam.
KanamycinPirfenidone may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pirfenidone.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pirfenidone.
LabetalolPirfenidone may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Pirfenidone.
LepirudinPirfenidone may increase the anticoagulant activities of Lepirudin.
LevobunololPirfenidone may decrease the antihypertensive activities of Levobunolol.
LidocaineThe serum concentration of Pirfenidone can be increased when it is combined with Lidocaine.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Pirfenidone.
LithiumThe serum concentration of Lithium can be increased when it is combined with Pirfenidone.
LornoxicamThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Pirfenidone.
LoxoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Pirfenidone.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pirfenidone.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pirfenidone.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pirfenidone.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pirfenidone.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pirfenidone.
MesalazinePirfenidone may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pirfenidone.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Pirfenidone.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Pirfenidone.
MetipranololPirfenidone may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.
MetoprololPirfenidone may decrease the antihypertensive activities of Metoprolol.
MetrizamidePirfenidone may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MexiletineThe serum concentration of Pirfenidone can be increased when it is combined with Mexiletine.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Pirfenidone.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Pirfenidone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Pirfenidone.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pirfenidone.
NadololPirfenidone may decrease the antihypertensive activities of Nadolol.
NadroparinPirfenidone may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pirfenidone.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pirfenidone.
NatalizumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when Pirfenidone is combined with NCX 4016.
NeomycinPirfenidone may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Nepafenac.
NetilmicinPirfenidone may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NevirapineThe serum concentration of Pirfenidone can be increased when it is combined with Nevirapine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pirfenidone.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Pirfenidone.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Pirfenidone.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.
OlsalazinePirfenidone may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pirfenidone.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Pirfenidone.
OrgoteinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Orgotein.
OtamixabanPirfenidone may increase the anticoagulant activities of Otamixaban.
OuabainOuabain may decrease the cardiotoxic activities of Pirfenidone.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pirfenidone.
OxprenololPirfenidone may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pirfenidone.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirfenidone.
PamidronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Parecoxib.
ParomomycinPirfenidone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololPirfenidone may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfatePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Pirfenidone.
PhenindionePirfenidone may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Pirfenidone can be decreased when it is combined with Phenobarbital.
PhenprocoumonPirfenidone may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pirfenidone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pirfenidone.
PindololPirfenidone may decrease the antihypertensive activities of Pindolol.
PiretanidePirfenidone may decrease the diuretic activities of Piretanide.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pirfenidone.
PlicamycinPirfenidone may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Pirfenidone.
PractololPirfenidone may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Pirfenidone.
PrimidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Pirfenidone can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Propacetamol.
PropranololPirfenidone may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Pirfenidone.
Protein CPirfenidone may increase the anticoagulant activities of Protein C.
ProtocatechualdehydePirfenidone may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Pirfenidone is combined with PTC299.
PuromycinPirfenidone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Pirfenidone.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Pirfenidone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Pirfenidone.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Pirfenidone.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pirfenidone.
ReviparinPirfenidone may increase the anticoagulant activities of Reviparin.
RibostamycinPirfenidone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe serum concentration of Pirfenidone can be decreased when it is combined with Rifampicin.
RilonaceptThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rilonacept.
RisedronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.
RivaroxabanPirfenidone may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pirfenidone.
RoflumilastRoflumilast may increase the immunosuppressive activities of Pirfenidone.
RopiniroleThe serum concentration of Pirfenidone can be increased when it is combined with Ropinirole.
SalicylamideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pirfenidone.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pirfenidone.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Pirfenidone.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Pirfenidone.
SeratrodastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Seratrodast.
SimeprevirThe serum concentration of Pirfenidone can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirfenidone.
SotalolPirfenidone may decrease the antihypertensive activities of Sotalol.
SpectinomycinPirfenidone may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Pirfenidone.
SpironolactonePirfenidone may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Pirfenidone is combined with SRT501.
StreptomycinPirfenidone may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinPirfenidone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazinePirfenidone may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pirfenidone.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pirfenidone.
SulodexidePirfenidone may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pirfenidone.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pirfenidone.
TacrolimusPirfenidone may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Pirfenidone.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Pirfenidone.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Pirfenidone.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Pirfenidone.
TenofovirThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tenofovir.
TenofovirThe serum concentration of Pirfenidone can be increased when it is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pirfenidone.
TepoxalinThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Teriflunomide.
TheophyllineThe serum concentration of Pirfenidone can be increased when it is combined with Theophylline.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pirfenidone.
TiclopidineThe serum concentration of Pirfenidone can be increased when it is combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tiludronate.
TimololPirfenidone may decrease the antihypertensive activities of Timolol.
TobramycinPirfenidone may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabTocilizumab may increase the immunosuppressive activities of Pirfenidone.
TofacitinibThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tofacitinib.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pirfenidone.
TorasemidePirfenidone may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Pirfenidone.
TranilastThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.
TrastuzumabTrastuzumab may increase the neutropenic activities of Pirfenidone.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Pirfenidone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Pirfenidone.
TriamterenePirfenidone may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Pirfenidone.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pirfenidone.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pirfenidone.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Pirfenidone.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Pirfenidone.
VedolizumabThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Vedolizumab.
WarfarinPirfenidone may increase the anticoagulant activities of Warfarin.
XimelagatranPirfenidone may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pirfenidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pirfenidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Furin is likely to represent the ubiquitous endoprotease activity within constitutive secretory pathways and capable of cleavage at the RX(K/R)R consensus motif.
Gene Name:
FURIN
Uniprot ID:
P09958
Molecular Weight:
86677.375 Da
References
  1. Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W: Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354(2):542-7. Epub 2007 Jan 10. [PubMed:17234158 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on September 27, 2016 02:27